TipRanks
Advertisement
Advertisement
Palvella Therapeutics price target raised to $232 from $227 at Canaccord
PremiumThe FlyPalvella Therapeutics price target raised to $232 from $227 at Canaccord
2M ago
Palvella Therapeutics: Strong Cash Runway and High-Confidence QTORIN Rapamycin Outlook Underpin New Buy Rating
Premium
Ratings
Palvella Therapeutics: Strong Cash Runway and High-Confidence QTORIN Rapamycin Outlook Underpin New Buy Rating
2M ago
High-Risk Warning for Investors in Palvella Therapeutics Securities
Premium
Company Announcements
High-Risk Warning for Investors in Palvella Therapeutics Securities
2M ago
What the $10B Crinetics Deal & $2.9B Soleno Acquisition Might Say About Palatin’s Rare-Obesity Opportunity
PremiumTipRanks NewswireWhat the $10B Crinetics Deal & $2.9B Soleno Acquisition Might Say About Palatin’s Rare-Obesity Opportunity
3M ago
Analyst Reiterates Buy on Palvella, Sees Market Overreaction to CVM Setback and Maintains $227 Price Target
Premium
Ratings
Analyst Reiterates Buy on Palvella, Sees Market Overreaction to CVM Setback and Maintains $227 Price Target
3M ago
Palvella Pharmaceuticals: Buy Rating Reiterated as QTORIN Regulatory Path Stays Intact; Price Target Unchanged at $225
Premium
Ratings
Palvella Pharmaceuticals: Buy Rating Reiterated as QTORIN Regulatory Path Stays Intact; Price Target Unchanged at $225
3M ago
Ligand price target raised to $345 from $330 at Craig-Hallum
PremiumThe FlyLigand price target raised to $345 from $330 at Craig-Hallum
3M ago
Palvella Therapeutics Highlights Growth Plans and QTORIN Progress
Premium
Company Announcements
Palvella Therapeutics Highlights Growth Plans and QTORIN Progress
3M ago
Palvella Therapeutics Adds Industry Veteran to Board
Premium
Company Announcements
Palvella Therapeutics Adds Industry Veteran to Board
3M ago

Trending

Name
Price
Price Change
S&P 500
―
Dow Jones
―
Nasdaq 100
―